Host directed therapies: COVID-19 and beyond-Reference-Cited by-同舟云学术

Host directed therapies: COVID-19 and beyond

Published:2021 Issue: Volume:2 Page:100058
ISSN:2590-2571
Container-title:Current Research in Pharmacology and Drug Discovery
language:en
Short-container-title:Current Research in Pharmacology and Drug Discovery

Author:

Tripathi Devavrat,Sodani Megha,Gupta Pramod Kumar,Kulkarni Savita

Publisher

Elsevier BV

Subject

General Medicine

Reference134 articles.

1. The Middle East respiratory syndrome (MERS);Azhar;Infect. Dis. Clin.,2019

2. A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: a broad spectrum antiviral candidate for treatment of COVID-19. The Lancet regional health;Backer;Europe,2021

3. The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia;Banerji;J. Clin. Invest.,2012

4. Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS);Batawi;Health Qual. Life Outcome,2019

5. Human papillomaviruses and the interferon response;Beglin;J. Interferon Cytokine Res. : the official journal of the International Society for Interferon and Cytokine Research,2009

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2;Molecules;2024-09-02

2. More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5-a]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus Replication;Journal of Medicinal Chemistry;2024-07-03

3. Identification of Dual Inhibitors Targeting Main Protease (M^pro) and Cathepsin L as Potential Anti-SARS-CoV-2 Agents;ACS Medicinal Chemistry Letters;2024-03-01

4. Identification of potential therapeutic targets for COVID-19 through a structural-based similarity approach between SARS-CoV-2 and its human host proteins;Frontiers in Genetics;2024-02-02

5. Efficacy and safety of MP1032 plus standard-of-care compared to standard-of-care in hospitalised patients with COVID-19: a multicentre, randomised double-blind, placebo-controlled phase 2a trial;The Lancet Regional Health - Europe;2024-02